Castellum Q1 Revenue Surges 23%; Record Backlog of $273.3M, but Stock Near Fair Value

What happened

Castellum reported Q1 2026 revenue of ~$14.6M, a 23% year-over-year increase driven by the ramp of the NAVAIR PMA-290 contract won in 2025, and entered Q2 with a record backlog of $273.3M, signaling strong near-term visibility. Despite the operational progress, the stock has already rallied ~405% over the past year, and our DCF analysis suggests an intrinsic value of ~$1.09 per share—only about 7% above the current price of ~$1.01. The company remains a microcap roll-up with thin free cash flow, persistent negative trailing operating income, and heavy customer concentration (72% of revenue from three government clients). Upcoming note maturities in 2025–2026 and a history of dilutive equity issuance add to the risk profile, even as profitability narrows. We see the Q1 results as consistent with the execution-dependent inflection story, but the valuation leaves little room for error.

Implication

While record backlog and rising revenue support the bull case that CTM is transitioning to a sustainable, cash-generative platform, the stock's 4x run has nearly eliminated any valuation margin of safety. We need at least two more consecutive quarters of positive operating income and free cash flow without equity dilution to upgrade the thesis. Key watch items include refinancing of the ~$8M notes due 2025–2026, maintaining low net leverage, and executing on backlog conversion at acceptable margins. If the company delivers these, a re-rating could occur, but any stumble—such as a contract loss or renewed cash burn—could trigger a sharp sell-off. For now, the risk/reward is balanced at current levels, favoring patience over conviction.

Thesis delta

Q1 results confirm the NAVAIR contract is ramping as expected, supporting the emerging profitability narrative, but the stock's ~405% run has already discounted much of this improvement. With the DCF-based fair value only ~7% above the current price, the margin of safety is thin given the microcap's inherent risks. We maintain our WAIT stance, requiring clearer evidence of sustainable profitability and non-dilutive refinancing before considering an upgrade.